Table 1 Clinical, laboratory and ultrasonographic characteristics of the 77 enrolled RA patients at study entrya
Characteristics | Data |
|---|---|
Demographics | |
Males/females, n (%) | 10 (13)/67 (87) |
Mean age, years (± SD) | 55.9 ± 14.3 |
Mean disease duration, months (± SD) | 119.2 ± 93.6 |
Caucasian, n (%) | 67 (87) |
Hispanic, n (%) | 9 (11.7) |
African, n (%) | 1 (1.3) |
Laboratory results | |
RF-positive, n (%) | 61 (79.2) |
ACPA-positive, n (%) | 58 (75.3) |
Mean ESR, mm/hour (± SD) | 31.8 ± 24.7 |
Clinical status (± SD) | |
Mean DAS28 score | 5.2 ± 1.2 |
Mean HAQ score | 1.26 ± 0.8 |
Concomitant treatment | |
Corticosteroids, n (%) | 48 (62.3) |
DMARDs, n (%) | |
Methotrexate | 37 (48.0) |
Hydroxychloroquine | 16 (20.8) |
Salazopyrin | 15 (19.5) |
Leflunomide | 9 (11.7) |
Mean US results (± SD) | |
Overall patient TES | 33.4 ± 21.9 |
MCP TES | 13.2 ± 8.1 |
PIP TES | 9.7 ± 8.1 |
MTP TES | 10.4 ± 8 |